• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Keywords » mitochondrial dysfunction

Items Tagged with 'mitochondrial dysfunction'

ARTICLES

3D heart in chest
Cardiovascular

ALDH9A1 identified as therapeutic target in CAVD

Oct. 18, 2024
Among the mechanisms causing calcific aortic valve disease (CAVD) are mitochondrial dysfunction and immune cell infiltration, but it is not well understood just how they impact CAVD pathogenesis.
Read More
Cardiovascular

CAV3 as therapeutic target for mitochondrial dysfunction in diabetic cardiomyopathy

May 8, 2024
Researchers from Huazhong University of Science and Technology and collaborators published results from a study that aimed to assess the potential role of caveolin 3 (CAV3) in mitochondrial function during diabetic cardiomyopathy (DCM).
Read More
Concept art for "unlocking the secrets of the mind"
Neurology/Psychiatric

Scientists find what prevents neuronal reprogramming in patients with mitochondrial deficiencies

Jan. 24, 2024
By Mar de Miguel
Reprogramming techniques to generate functional neurons could improve neurodegeneration in the future. A group of researchers from the Institute for Stem Cell Research (ISF) in Germany have found the pathways that play a role in improving the conversion of astrocytes into neurons.
Read More
Elderly woman holding illustration of brain with missing puzzle piece

New blood test to detect Parkinson’s disease earlier

Sep. 14, 2023
By Shani Alexander
An international team of researchers have developed a new blood test that could detect Parkinson’s disease earlier than current methods. The test, a real-time PCR-based assay, called Mito Dnadx, uses blood to identify damage to mitochondrial DNA (mtDNA) caused by the neurodegenerative condition. Based on the findings published in the journal Science Translational Medicine, the test could allow rapid, noninvasive and accurate identification of Parkinson’s disease (PD) before it causes much damage to the nervous system.
Read More
Scanning electron micrograph of a cell infected with the Omicron strain of SARS-CoV-2 virus particles
Infection

Viral alteration of mitochondrial function may trigger severe COVID-19

Aug. 14, 2023
By Mar de Miguel
How severe a viral infection is depends on how much the virus is replicating, damaging cells as it does so, and on the response of the immune system. Or so one would think. “Some of the most severe cases of COVID-19 are happening in the absence of replicating virus,” Joseph Guarnieri told BioWorld. In work published in Science Translational Medicine on Aug. 9, 2023, Guarnieri and his colleagues have described how those severe cases unfold, even as there is no replicating virus to be found.
Read More
3D rendered illustration of a synapse cross-section
Neurology/Psychiatric

Reduced RNA editing reveals mitochondrial dysfunction in schizophrenia

April 11, 2023
By Mar de Miguel
RNA editing in schizophrenia (SCZ)-associated genes was decreased in postmortem brains of individuals of European descent, according to a study from the University of California, Los Angeles (UCLA). The scientists obtained the RNA editome from SCZ brains to detect the sequence changes in their RNA and observed hypoediting in noncoding regions related to mitochondrial function, such as the mitofusin-1 (MFN1) gene.
Read More
Fundus image of eye with age-related macular degeneration.
Ocular

UNI-494 improves contrast vision in rat models of geographic atrophy

Nov. 22, 2022
Unicycive Therapeutics Inc. has announced key efficacy findings with UNI-494 in animal models of geographic atrophy (GA). UNI-494 is a mitochondrial potassium channel (mitoKATP) activator in development for treating diseases affected by mitochondrial dysfunction, such as kidney, liver and ocular diseases.
Read More
Mitochondria illustration
Genetic/congenital

Pretzel Therapeutics launches with focus on mitochondrial biology

Sep. 13, 2022
Pretzel Therapeutics Inc. has launched with a $72.5 million series A financing to pioneer novel therapies to modulate mitochondrial function to treat rare genetic diseases and common diseases of aging.
Read More
Mitochondria illustration

Minovia and Astellas to develop mitochondrial dysfunction therapies

Aug. 3, 2021
By Lee Landenberger
Minovia Therapeutics Ltd. will collaborate with Astellas Pharma Inc. to research, develop and commercialize cell therapy programs for treating diseases brought on by mitochondrial dysfunction. The candidates will come from Astellas’ genetically engineered, induced pluripotent stem cells. Haifa, Israel-based Minovia will receive $20 million in cash up front.
Read More
Mitochondria illustration

Minovia and Astellas to develop mitochondrial dysfunction therapies

July 30, 2021
By Lee Landenberger
Minovia Therapeutics Ltd. will collaborate with Astellas Pharma Inc. to research, develop and commercialize cell therapy programs for treating diseases brought on by mitochondrial dysfunction. The candidates will come from Astellas’ genetically engineered, induced pluripotent stem cells. Haifa, Israel-based Minovia will receive $20 million in cash up front.
Read More
More Articles Tagged with 'mitochondrial dysfunction'

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 9, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe